Dendritic Cell Vaccine (DCVax-L) - Revision history

Lazy at 08:27, 18 January 2025

2025-01-18T08:27:14Z

← Older revision		Revision as of 01:27, 18 January 2025
Line 83:		Line 83:
	greater than 21.5 months.		greater than 21.5 months.
	\|links=https://www.onclive.com/view/dcvax-l-improves-survival-in-glioblastoma, https://medicalxpress.com/news/2022-11-phase-clinical-trial-brain-cancer.html, https://www.targetedonc.com/view/dcvax-l-extends-survival-in-newly-diagnosed-and-recurrent-gbm		\|links=https://www.onclive.com/view/dcvax-l-improves-survival-in-glioblastoma, https://medicalxpress.com/news/2022-11-phase-clinical-trial-brain-cancer.html, https://www.targetedonc.com/view/dcvax-l-extends-survival-in-newly-diagnosed-and-recurrent-gbm
	}}		\|overview=The Dendritic Cell Vaccine (DCVax-L) is an investigational vaccine therapy for glioblastoma multiforme (GBM) currently in Phase 3 clinical trials, showing promising median overall survival rates of 19.3 months for newly diagnosed patients and 13.2 months for those with recurrent disease. While it is well-tolerated with manageable side effects, its efficacy highlights the potential for enhancing patient outcomes in a challenging treatment landscape.}}

Lazy at 19:33, 25 December 2024

2024-12-25T19:33:47Z

← Older revision		Revision as of 12:33, 25 December 2024
Line 1:		Line 1:
	{{TreatmentInfo		{{TreatmentInfo
	\|drug_name=Dendritic Cell Vaccine (DCVax-L)		\|drug_name=Dendritic Cell Vaccine (DCVax-L)
	\|treatment_category=Vaccines~~, Clinical Trials, Right to Try~~		\|treatment_category=Vaccines
	\|FDA_approval=Under investigation; not yet FDA-approved		\|FDA_approval=Under investigation; not yet FDA-approved
	\|used_for=Glioblastoma Multiforme (GBM), both newly diagnosed and recurrent		\|used_for=Glioblastoma Multiforme (GBM), both newly diagnosed and recurrent

Lazy at 19:25, 25 December 2024

2024-12-25T19:25:23Z

← Older revision		Revision as of 12:25, 25 December 2024
Line 1:		Line 1:
	{{TreatmentInfo		{{TreatmentInfo
	\|drug_name=Dendritic Cell Vaccine (DCVax-L)		\|drug_name=Dendritic Cell Vaccine (DCVax-L)
	\|treatment_category=Vaccines		\|treatment_category=Vaccines, Clinical Trials, Right to Try
	~~\|treatment_category=Vaccines~~
	~~\|treatment_category=~~Clinical Trials
	~~\|treatment_category=~~Right to Try
	\|FDA_approval=Under investigation; not yet FDA-approved		\|FDA_approval=Under investigation; not yet FDA-approved
	\|used_for=Glioblastoma Multiforme (GBM), both newly diagnosed and recurrent		\|used_for=Glioblastoma Multiforme (GBM), both newly diagnosed and recurrent

Lazy at 19:23, 25 December 2024

2024-12-25T19:23:25Z

← Older revision		Revision as of 12:23, 25 December 2024
Line 1:		Line 1:
	{{TreatmentInfo		{{TreatmentInfo
	\|drug_name=Dendritic Cell Vaccine (DCVax-L)		\|drug_name=Dendritic Cell Vaccine (DCVax-L)
			\|treatment_category=Vaccines
	\|treatment_category=Vaccines		\|treatment_category=Vaccines
	\|treatment_category=Clinical Trials		\|treatment_category=Clinical Trials

Lazy at 19:22, 25 December 2024

2024-12-25T19:22:58Z

← Older revision		Revision as of 12:22, 25 December 2024
Line 2:		Line 2:
	\|drug_name=Dendritic Cell Vaccine (DCVax-L)		\|drug_name=Dendritic Cell Vaccine (DCVax-L)
	\|treatment_category=Vaccines		\|treatment_category=Vaccines
			\|treatment_category=Clinical Trials
			\|treatment_category=Right to Try
	\|FDA_approval=Under investigation; not yet FDA-approved		\|FDA_approval=Under investigation; not yet FDA-approved
	\|used_for=Glioblastoma Multiforme (GBM), both newly diagnosed and recurrent		\|used_for=Glioblastoma Multiforme (GBM), both newly diagnosed and recurrent

Lazy at 19:22, 25 December 2024

2024-12-25T19:22:32Z

← Older revision		Revision as of 12:22, 25 December 2024
Line 2:		Line 2:
	\|drug_name=Dendritic Cell Vaccine (DCVax-L)		\|drug_name=Dendritic Cell Vaccine (DCVax-L)
	\|treatment_category=Vaccines		\|treatment_category=Vaccines
	~~\|treatment_category=Clinical Trials~~
	~~\|treatment_category=Right to Try~~
	\|FDA_approval=Under investigation; not yet FDA-approved		\|FDA_approval=Under investigation; not yet FDA-approved
	\|used_for=Glioblastoma Multiforme (GBM), both newly diagnosed and recurrent		\|used_for=Glioblastoma Multiforme (GBM), both newly diagnosed and recurrent

Lazy at 19:21, 25 December 2024

2024-12-25T19:21:24Z

← Older revision		Revision as of 12:21, 25 December 2024
Line 1:		Line 1:
	{{TreatmentInfo		{{TreatmentInfo
	\|drug_name=Dendritic Cell Vaccine (DCVax-L)		\|drug_name=Dendritic Cell Vaccine (DCVax-L)
	\|treatment_category=~~Specialized Treatments~~		\|treatment_category=Vaccines
	\|treatment_category=Clinical Trials		\|treatment_category=Clinical Trials
	\|treatment_category=Right to Try		\|treatment_category=Right to Try
Line 10:		Line 10:
	\|OS_without=Median overall survival for GBM is typically 15-17 months from diagnosis, or 8 months from recurrence		\|OS_without=Median overall survival for GBM is typically 15-17 months from diagnosis, or 8 months from recurrence
	\|OS_with=Median overall survival of 19.3 months from randomization (22.4 months from surgery) for newly diagnosed GBM patients; 13.2 months from relapse for recurrent GBM		\|OS_with=Median overall survival of 19.3 months from randomization (22.4 months from surgery) for newly diagnosed GBM patients; 13.2 months from relapse for recurrent GBM
	~~\|treatment_category=Vaccines~~
	\|PFS_without=Data not specified		\|PFS_without=Data not specified
	\|PFS_with=Median progression-free survival of 6.2 months in the DCVax-L arm, compared to 7.6 months in the placebo group, though this difference was not statistically significant		\|PFS_with=Median progression-free survival of 6.2 months in the DCVax-L arm, compared to 7.6 months in the placebo group, though this difference was not statistically significant

Lazy at 13:43, 25 December 2024

2024-12-25T13:43:47Z

← Older revision		Revision as of 06:43, 25 December 2024
Line 10:		Line 10:
	\|OS_without=Median overall survival for GBM is typically 15-17 months from diagnosis, or 8 months from recurrence		\|OS_without=Median overall survival for GBM is typically 15-17 months from diagnosis, or 8 months from recurrence
	\|OS_with=Median overall survival of 19.3 months from randomization (22.4 months from surgery) for newly diagnosed GBM patients; 13.2 months from relapse for recurrent GBM		\|OS_with=Median overall survival of 19.3 months from randomization (22.4 months from surgery) for newly diagnosed GBM patients; 13.2 months from relapse for recurrent GBM
			\|treatment_category=Vaccines
	\|PFS_without=Data not specified		\|PFS_without=Data not specified
	\|PFS_with=Median progression-free survival of 6.2 months in the DCVax-L arm, compared to 7.6 months in the placebo group, though this difference was not statistically significant		\|PFS_with=Median progression-free survival of 6.2 months in the DCVax-L arm, compared to 7.6 months in the placebo group, though this difference was not statistically significant

69.163.248.232: Updated category= to treatment_category= in TreatmentInfo template

2024-11-12T18:43:18Z

Updated category= to treatment_category= in TreatmentInfo template

← Older revision		Revision as of 11:43, 12 November 2024
Line 1:		Line 1:
	{{TreatmentInfo		{{TreatmentInfo
	\|drug_name=Dendritic Cell Vaccine (DCVax-L)		\|drug_name=Dendritic Cell Vaccine (DCVax-L)
	\|~~category~~=Specialized Treatments		\|treatment_category=Specialized Treatments
	\|~~category~~=Clinical Trials		\|treatment_category=Clinical Trials
	\|~~category~~=Right to Try		\|treatment_category=Right to Try
	\|FDA_approval=Under investigation; not yet FDA-approved		\|FDA_approval=Under investigation; not yet FDA-approved
	\|used_for=Glioblastoma Multiforme (GBM), both newly diagnosed and recurrent		\|used_for=Glioblastoma Multiforme (GBM), both newly diagnosed and recurrent

Lazy at 17:31, 11 November 2024

2024-11-11T17:31:47Z

← Older revision		Revision as of 10:31, 11 November 2024
Line 1:		Line 1:
	{{TreatmentInfo		{{TreatmentInfo
	\|drug_name=Dendritic Cell Vaccine (DCVax-L)		\|drug_name=Dendritic Cell Vaccine (DCVax-L)
			\|category=Specialized Treatments
			\|category=Clinical Trials
			\|category=Right to Try
	\|FDA_approval=Under investigation; not yet FDA-approved		\|FDA_approval=Under investigation; not yet FDA-approved
	\|used_for=Glioblastoma Multiforme (GBM), both newly diagnosed and recurrent		\|used_for=Glioblastoma Multiforme (GBM), both newly diagnosed and recurrent